comparemela.com
Home
Live Updates
Head Of Development At Sangamo - Breaking News
Pages:
Latest Breaking News On - Head of development at sangamo - Page 2 : comparemela.com
Sangamo Therapeutics, Inc : Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Preliminary data showed that isaralgagene civaparvovec, or ST-920, was generally well tolerated - All four patients in the first two dose cohorts exhibited above normal a-Gal A activity, which was maintained
Aaron feingold
Rob schott
Exchange commission
Drug administration
Head of development at sangamo
European medicines agency
Sangamo therapeutics inc
Events presentations
Orphan drug
Orphan medicinal product
European medicines
Fabry disease
Sangamo therapeutics
Annual report
Quarterly report
vimarsana © 2020. All Rights Reserved.